Use of a new transdermal delivery system for estrogen replacement therapy in postmenopausal women.
This study reports on the use of a new transdermal delivery system for estrogen replacement therapy. This was a 12 week open multicenter trial using patches that delivered 0.05 mg/24 hour of 17 beta-estradiol applied twice weekly, every 72 hours, with one week interval after each 3 weeks. Results indicate an overall significant improvement on climacteric complaints with a highly significant and time-related reduction in the two most frequent symptoms: hot flushes and night sweating. Neither local nor systemic side effects were prevalent. By the end of treatment mean plasma levels of estradiol and FSH were 50.6 pg/ml and 46.8 mIU/ml, respectively. It is concluded that this new system of transdermal estrogen replacement therapy significantly reduces the main postmenopausal symptoms, produces adequate plasma estradiol levels and allows good compliance to treatment.
Figueroa-Casas
P R
PR
Centro de Reproducción Humana, Hospital Saenz-Peña, Rosario, Argentina.
Alfonsin
A
A
Arrighi
A
A
Bluvstein
G
G
Del Castillo
R
R
Goldsman
T
T
Inglesi
J
J
Itala
J
J
Novelli
J
J
Monti
C
C
D000279:Administration, Cutaneous; D002979:Climacteric / Q000187:drug effects*; D004334:Drug Administration Schedule; D004958:Estradiol / Q000008:administration & dosage* / Q000009:adverse effects / Q000097:blood; D015914:Estrogen Replacement Therapy; D005260:Female; D005640:Follicle Stimulating Hormone / Q000097:blood; D006801:Humans; D008593:Menopause / Q000187:drug effects*; D008875:Middle Aged; D016896:Treatment Outcome
D004958:Estradiol; D005640:Follicle Stimulating Hormone